Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis

Standard treatment for locally advanced (stage III-IV) head and neck squamous cell cancer (LA-HNSCC) is concurrent chemoradiation therapy (CCRT) with cisplatin 100 mg/m(2) every 3 weeks. For medically unfit patients susceptible to treatment-related adverse events, low-dose weekly cisplatin (30–40 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, So Yeon, Choi, Yoon Seok, Song, Ik-Chan, Park, Sang Gon, Keam, Bhumsuk, Yang, Young Jun, Song, Eun-Kee, Lee, Hyo Jin, Cho, Sang-Hee, Shim, Hyeok, Park, Keon Uk, Lee, Ki-Hyeong, Jo, Deog-Yeon, Jo, Ihn-Seong, Yun, Hwan-Jung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392979/
https://www.ncbi.nlm.nih.gov/pubmed/29794758
http://dx.doi.org/10.1097/MD.0000000000010778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6392979/
https://www.ncbi.nlm.nih.gov/pubmed/29794758
http://dx.doi.org/10.1097/MD.0000000000010778

Ejemplares similares